MedTrace Logo

MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

NCT00501371 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2011-12-14

No results posted yet for this study

Summary

Phase III, Randomized, double-blind, parallel placebo-controlled study. Two arms: MCS (30mg/day) vs. placebo.

Subproject MCS-2: alpha-blocker naïve subjects

Subproject MCS-3: subjects responding poorly to alpha-blocker

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

MCS

soft-gel capsule, 15 mg/cap., Qd, 12 weeks

DRUG

Placebo

soft-gel capsule, Qd, 12 weeks

Sponsors & Collaborators

  • Health Ever Bio-Tech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yeong-Shiau Pu, MD, PhD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501371 on ClinicalTrials.gov